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A kinome-wide screen identifies a CDKL5-SOX9
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Renal tubular epithelial cells (RTECs) perform the essential function of maintaining the
constancy of body fluid composition and volume. Toxic, inflammatory, or hypoxic-insults to
RTECs can cause systemic fluid imbalance, electrolyte abnormalities and metabolic waste
accumulation- manifesting as acute kidney injury (AKI), a common disorder associated with
adverse long-term sequelae and high mortality. Here we report the results of a kinome-wide
RNAi screen for cellular pathways involved in AKI-associated RTEC-dysfunction and cell
death. Our screen and validation studies reveal an essential role of Cdkl5-kinase in RTEC cell
death. In mouse models, genetic or pharmacological Cdkl5 inhibition mitigates nephrotoxic
and ischemia-associated AKI. We propose that Cdkl5 is a stress-responsive kinase that
promotes renal injury in part through phosphorylation-dependent suppression of pro-survival
transcription regulator Sox9. These findings reveal a surprising non-neuronal function of
Cdkl5, identify a pathogenic Cdkl5-Sox9 axis in epithelial cell-death, and support CDKL5
antagonism as a therapeutic approach for AKI.
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The ability of vertebrates to maintain a stable, relativelyconstant “internal milieu” is inextricably linked tothe function of the kidneys1. Through a continuous
filtration–reabsorption process, kidneys regulate the fluid and
molecular composition of blood. Within the kidneys, the renal
tubular epithelial cells (RTECs) carry out the enormous task of
selective reabsorption of water, ions, and essential nutrients, as
well as excretion of metabolic waste, thereby converting the
glomerular filtrate into a concentrated urine whose composition
is constantly fine-tuned to maintain organismal homeostasis.
RTEC dysfunction can thus lead to systemic electrolyte and fluid
imbalances along with accumulation of metabolic and toxic waste
triggering deleterious systemic effects and multi-organ failure.
Numerous clinical conditions such as sepsis, cardiac surgery,
drug toxicities, cancer therapy, and rhabdomyolysis are associated
with inflammatory, toxic, and hypoxic insults to RTECs2–6. The
resulting RTEC dysfunction and cell death7 are the hallmarks and
the underlying cause of acute kidney injury (AKI), a common
disorder that predominantly develops in hospitalized patients8.
Due to the lack of treatment options, annually an estimated 2
million people worldwide die of AKI9. Importantly, the patients
that recover from an AKI episode are at increased risk of devel-
oping chronic kidney disease, end-stage renal disease, and car-
diovascular dysfunction—disorders associated with significant
morbidity and mortality10,11. Over the past decade, it has become
apparent that the pathophysiology of AKI is exceedingly com-
plex12. Multiple molecular and cellular pathways are involved in
RTEC dysfunction and cell death7. Vascular and immune cells
also contribute to renal impairment13–15. Recent advancements in
our understanding of the pathophysiological basis of AKI have
however not yet resulted in clinical benefits, in part, due to the
non-druggable nature of several identified molecular targets and
associated pathways. One possible way to transcend these diffi-
culties is to utilize unbiased functional genomic screening to
systematically uncover the role of “druggable genes” in AKI.
Of the estimated ~20,000 protein-coding genes in the human
genome, ~10% encode proteins that can currently be targeted by
small-molecule drugs, a group defined as “druggable genome”16.
Protein kinases17 are one of the largest family in the “druggable
genome”, along with G-coupled protein receptors. Due to the
potential widespread role of kinases in disease pathogenesis, as
well as suitable pharmacological properties and clinical safety
profile of kinase inhibitors, protein kinases have emerged as
attractive therapeutic targets18,19. Nevertheless, the underlying
biology of the majority of kinases remains yet to be fully eluci-
dated. Moreover, the role of protein kinases in the pathogenesis of
non-oncological diseases, especially AKI, remains underexplored.
Here, we have used a kinome-wide screening approach to
identify kinases that contribute to RTEC cell death in order to
reveal therapeutic targets for AKI. Initial in vitro RNAi-based
screening and subsequent in vivo validation experiments identi-
fied cyclin-dependent kinase-like 5 (Cdkl5) also known as serine/
threonine kinase 9 (Stk9)20 as a key regulator of renal cell death
and injury. CDKL5 has mostly been studied for its role in human
neuronal development since mutations in this X-linked gene are
associated with neurodevelopmental disorders including early
onset seizures21,22. Surprisingly, we have uncovered a previously
unrecognized function of Cdkl5 as a crucial regulator of renal
injury and identified the transcription factor Sox9 as one of its
crucial downstream target.
Results
Identification of kinases involved in RTEC cell death. We
performed a kinome-wide small-interfering RNA (siRNA) screen
in BUMPT cells in order to identify protein kinases that regulate
renal epithelial-cell death. High transient transfection efficiency
(~95%) of this murine RTEC cell line makes it a suitable model
for high-throughput (siRNA) screening assays. For the primary
screen, BUMPT cells were transfected with either control siRNAs
(non-targeting, Pkcδ and Plk1) or siRNAs targeting protein
kinases, phosphatases, and related targets (780 genes, Dharma-
con), followed by induction of cell death by treatment with cis-
platin and assessment of cellular viability by cell-titer glo assay
(Fig. 1a). Cisplatin-induced cell death in BUMPT cells partially
mimics conditions observed during cisplatin-associated AKI23.
The in vitro screening assay involved the treatment of
BUMPT cells with 15 µM cisplatin, which reduced the cell via-
bility by ~75% in 48 h in the untransfected and control siRNA-
(non-targeting) transfected cells (Supplementary Fig. 1a, b).
Cisplatin-induced cell death was partially ameliorated by protein
kinase c δ (Pkcδ) knockdown (positive control), which is an
established24 pro-apoptotic gene and significantly increased by
polo-like kinase 1 (Plk1) knockdown (negative control).
The primary screen was carried out in triplicate, and
subsequent data analysis (Fig. 1b, c) yielded seven hit candidates
(Supplementary Table 1) that mitigated cell death to an extent
that was significantly (p < 0.05, one-way ANOVA followed by
Dunnett’s test) greater than the positive control (Pkcδ siRNA).
For stringent validation of these identified hits, we performed
confirmatory experiments by employing distinct siRNAs/
shRNAs, cell lines, and assay systems. In the secondary screening,
we utilized dissimilar siRNAs from a different source (Sigma) and
used different cell viability and cell-death assays (MTT, Trypan
Blue, and Caspase assay). Secondary screening in BUMPT cells
(Fig. 1d and Supplementary Fig. 1c, d) validated three out of
seven hits obtained in the primary screen. Similar studies in HK-2
(human kidney-2) cells, a human RTEC cell line showed that
CDKL5 knockdown significantly reduced cisplatin-induced cell
death (Fig. 1e and Supplementary Fig. 1e, f). Cdkl5 was the top hit
in both the primary and secondary screens and hence we selected
it for further confirmation.
The CDKL family (CDKL1–5) comprises five members that
share structural similarities with CDKs as well as mitogen-
activated protein kinases (MAPKs); however, their biological
functions and linked signal transduction pathways remain
obscure25,26. CDKL5 is highly expressed in the brain and CDKL5
loss-of-function mutations are associated with neurodevelop-
mental disorders in humans, although the underlying mechan-
isms are incompletely understood27. It also remains unknown if
CDKL5 kinase controls any biological processes in nonneuronal
tissues, such as testes and kidneys, where it is known to be
expressed20,28.
Mechanisms underlying CDKL5 activation also remain
unclear. However, similar to MAPKs, CDKL5 contains the TEY
sequence within its activation loop (Fig. 1f). The TEY motif in the
extracellular signal-regulated kinases (ERKs) undergoes dual
phosphorylation resulting in kinase activation. This mechanism
of activation is in most cases initiated by other upstream kinases
or in some cases via autophosphorylation as has been proposed
for ERK7 and CDKL529. To confirm the role of Cdkl5 kinase in
RTEC cell death, we carried out tertiary screening where we
silenced Cdkl5 expression in BUMPT cells using a shRNA
targeting the 3′ UTR (untranslated region) of Cdkl5 gene and
carried out “add-back” experiments by overexpressing shRNA-
resistant Cdkl5 constructs, including wild-type, kinase-dead, and
TEY mutants (Fig. 1g, h and Supplementary Fig. 1g, h). We found
that shRNA-mediated Cdkl5 knockdown reduces cisplatin-
induced cell death, and importantly this phenotype was reversed
by wild-type but not kinase-dead or TEY-mutant Cdkl5 over-
expression. Of note, overexpression of WT Cdkl5 in the control
cells did not influence RTEC cell death. This may be due to
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limiting upstream activation signals, since unlike the wild-type
Cdkl5, overexpression of catalytically active Cdkl5 (lacking the
regulatory domain) increases cisplatin-associated RTEC cell death
(Supplementary Fig. 1i–k). Collectively, our siRNA screening and
validation studies identified Cdkl5 kinase (Fig. 1h) as a crucial,
previously unknown regulator of renal epithelial-cell death.
Cdkl5-kinase activity increases in RTECs during AKI. While we
used a cisplatin-based in vitro screening method to identify
putative regulators of RTEC cell death and dysfunction, our overall
goal was to identify and validate targets that contribute to the
pathogenesis of AKI associated with multiple etiologies. Hence,
confirmatory in vivo studies were carried out in two distinct and
widely used models of AKI, namely, ischemia–reperfusion injury
and cisplatin-associated AKI30. In these mouse models, the onset
of AKI was determined by three diverse indicators of renal
structure and function: accumulation of nitrogenous waste (blood
urea nitrogen and serum creatinine), biomarkers (kidney injury
molecule-1 [Kim1]31 and neutrophil gelatinase-associated lipocalin
[Ngal]32), and histological analysis (H&E staining and renal
damage score) (Fig. 2a–g). In the ischemic injury model, AKI onset
occurs 24-h post surgery, while in the cisplatin-associated renal
injury model, renal impairment is seen 72-h post injection. We
found that Cdkl5 protein levels showed significant variations, but
overall, we observed marginal increase during the early phases of
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AKI, followed by reduction at later timepoints (Fig. 2h). To
examine the Cdkl5 phosphorylation status in the activation loop,
we generated a phospho-threonine-169 antibody that recognizes
phosphorylated threonine within the TEY motif (Supplementary
Fig. 2). Western blot analysis showed that Cdkl5 phosphorylation
increased during AKI (Fig. 2h). Subsequently, kinase assays
showed increased Cdkl5 activity in renal tissues during the early
stages of AKI (Fig. 2i–k).
We next investigated whether the increased Cdkl5 activity is
localized in the RTECs—the major cell type that is impacted
during AKI7. In order to label and isolate RTECs from murine
kidneys, we crossed the ROSAmT/mG strain with the renal tubular
epithelial-cell-specific Ggt1-Cre (gamma-glutamyltransferase-1)
mice to generate transgenic mice that express membrane-
localized green fluorescent protein (GFP) in the tubular epithelial
cells (Fig. 2i and Supplementary Fig. 3). We then isolated GFP-
positive cells from the kidneys of untreated and cisplatin-treated
mice (Fig. 2m), followed by examination of Cdkl5 kinase activity
(Fig. 2n). These studies confirmed that Cdkl5 activity increases in
RTECs (GFP-positive cells) early during the development of AKI.
Furthermore, increased Cdkl5-kinase activity was also observed
in murine models of rhabdomyolysis and folic acid (FA)-
associated AKI, as well as in a previously described33 porcine
model of ischemic AKI (Supplementary Fig. 4a–g). In support of
the in vivo studies, increased Cdkl5 activity was also observed in
primary RTECs under multiple stress conditions, including
cisplatin, hydrogen peroxide, hypoxia, and hemin treatments
(Supplementary Fig. 4h, i). Under these conditions, increased
Cdkl5 activity seemed to be independent of the cell-cycle phase.
In summary, these results show that irrespective of the nature of
the initial injury, an increase in Cdkl5 kinase activity is a common
phenomenon during AKI, signifying a potential functional role in
disease pathogenesis.
Cdkl5 gene ablation in epithelial cells mitigates AKI. We next
sought to examine the consequence of Cdkl5 gene deletion on the
severity of AKI. Germline Cdkl5-knockout mice are viable27,
although they exhibit certain nonlethal neuronal phenotypes. We
found that Cdkl5-knockout mice do not have any overt renal
abnormalities under normal conditions (Supplementary Fig. 5a,
b), which gave us the opportunity to examine the effect of Cdkl5
deficiency on the severity of AKI. We found that as compared
with wild-type littermates, Cdkl5−/y mice showed protection from
ischemia-associated AKI as revealed by multiple indicators: BUN,
creatinine, Kim1 expression, and histological analysis (Supple-
mentary Fig. 6a–e). Likewise, Cdkl5−/y mice displayed resistance
to cisplatin-associated AKI (Supplementary Fig. 6f–i).
To probe the RTEC-specific role of Cdkl5 in the pathogenesis
of AKI, we generated Cdkl5 conditional knockout mice (Cdkl5PT
−/y) by crossing the Cdkl5-floxed mice with the Ggt1-Cre mice. In
Ggt1-Cre mice, Cre recombinase is expressed in RTECs 7–10 days
after birth, such that Cre expression most likely occurs after the
completion of renal development34. We found that normal renal
function (Supplementary Fig. 5c, d) is unaffected by Cdkl5
deficiency (Fig. 3a). Importantly, Cdkl5 gene ablation in RTECs
provided significant protection from ischemia-associated
(Fig. 3b–e) and cisplatin-mediated (Fig. 3f–i) AKI. To investigate
the effect of Cdkl5 deficiency on renal cell death and to exclude
the possibility of nonspecific compensatory changes, we cultured
primary RTECs from the Cdkl5-floxed mice and carried out
Cdkl5 deletion under in vitro conditions using lentivirus-
mediated Cre expression (Fig. 3j, k). We found that Cdkl5
deletion provides significant protection from cisplatin-mediated
cell death. Collectively, these studies suggested that Cdkl5 kinase
plays a pathogenic role during the development of AKI.
Cdkl5 phosphorylates Sox9 during AKI. We next pursued the
Cdkl5-dependent mechanisms that contribute to renal dysfunc-
tion. CDKL5 regulates several neuronal functions; however, the
downstream signaling pathways remain incompletely understood.
Previous reports have described functional interactions of CDKL5
with other proteins with important neuronal functions25,35–39.
Whether these interactions are relevant in renal epithelial cells is
however unclear. Therefore, in an attempt to understand the
mechanistic basis of Cdkl5-dependent renal injury, we sought to
identify Cdkl5-interacting proteins. To this end, we immuno-
precipitated (IP) endogenous Cdkl5 from ischemic renal tissues
and found that an ~65-kDa protein was associated with Cdkl5.
Mass spectrometric analysis identified this protein as the tran-
scription factor Sox9 (sex-determining region Y (SRY) box 9)
(Fig. 4a). Sox9 is a member of Sox family, which are a group of
transcription factors that have essential roles in cell-fate deter-
mination during embryonic development and adult tissue
homeostasis40. Interestingly, Sox9 is also known to suppress
cell death during development, adult tissue homeostasis, and
oncogenesis41,42.
We confirmed that Cdkl5 interacts with Sox9, by Cdkl5-IP and
reverse IP (Sox9-IP) experiments (Supplementary Fig. 7). Nota-
bly, Sox9 protein is expressed at low amounts in control kidneys,
and its expression is induced during AKI (input blots,
Supplementary Fig. 7). Given the physical association between
Cdkl5 and Sox9 in renal tissues, we considered if Sox9 is a
previously unknown Cdkl5 substrate. Based on sequence analysis
and global phospho-proteomics data43, we identified five putative
Fig. 1 A kinome-wide screen uncovers protein kinases involved in RTEC cell death. a Scheme depicting the assay conditions used in the primary siRNA
screen. BUMPT cells were transfected with Kinome-wide siRNA library (Dharmacon), followed by cisplatin treatment and cell-titer-glo-based viability
assay. b Results of primary RNAi screening, shown by plotting the relative survival post cisplatin treatment of individual siRNA-targeted genes obtained
from triplicate samples. c Kinome map (KinMap) depicting kinases identified in the primary screen. d Validation of primary hits by distinct siRNAs (Sigma)
in BUMPT cells. Survival data (MTT assay) are presented as individual data points (n= 4 biologically independent samples), from one out of three
independent experiments, all producing similar results. e Further secondary screening was carried out in HK-2 cells, by RNAi-mediated knockdown of
indicates genes, followed by MTT-based cellular viability assay. Data are presented as individual data points (n= 4 biologically independent samples), from
one out of three independent experiments, all producing similar results. f Schematic representation of CDKL5, the top hit and other members of CMGC
kinase family. g, h Tertiary screening was carried for the top hit (Cdkl5) by shRNA-mediated knockdown in BUMPT cells and “add back” of wild-type and
mutant Cdkl5. Cellular viability assays (MTT) showed that shRNA-mediated Cdkl5 knockdown protects BUMPT cells from cisplatin-mediated cell death, an
effect that was reversed by re-introduction of wild-type but not mutant Cdkl5. Data are presented as individual data points (n= 4 biologically independent
samples), from one out of three independent experiments, all producing similar results. Representative western blot results demonstrating shRNA-
mediated CDKL5 kinase knockdown and introduction of untagged wild-type, kinase-dead (KD), and TEY/AEF Cdkl5 constructs. Data are representative of
three independent experiments. In all the bar graphs, experimental values are presented as mean ± s.e.m. The height of error bar= 1 s.e. and p < 0.05 was
indicated as statistically significant. One-way ANOVA followed by Dunnett’s (d, e) or Tukey’s multiple-comparison test (h) was carried out, and statistical
significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
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phosphorylation sites in the Sox9 protein. We then tested the
ability of purified Cdkl5 to phosphorylate wild-type and Ser-to-
Ala Sox9 mutants. We found that Cdkl5 could phosphorylate
wild-type Sox9 (Fig. 4b). Importantly, Ser-199 was found to be
the major site of phosphorylation since Ser-to-Ala mutation at
this site significantly abolished Cdkl5-mediated Sox9 phosphor-
ylation (Fig. 4b). The Ser-199 site is evolutionarily conserved
(Fig. 4c); however, the functional consequence of phosphoryla-
tion at this site has not been previously studied.
To ascertain the functional consequence of Cdkl5-mediated
Sox9 phosphorylation, we investigated the potential effect of
phosphorylation at Ser-199 site on Sox9 localization and stability.
We generated S199A (non-phosphorylatable) and S199D (phos-
pho-mimetic) Sox9 mutants and then examined their localization
and stability in BUMPT cells. Sox9 subcellular localization was
predominantly nuclear and was unaffected by S199A or S199D
mutation (Supplementary Fig. 8a). Interestingly, cycloheximide
(CHX) pulse-chase experiments showed that S199A mutant was
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Fig. 2 CDKL5 activity increases in renal tubular epithelial cells during AKI. a–c Bilateral renal ischemia was induced in male wild-type (C57BL/6) mice
for 30min followed by reperfusion for indicated timepoints. Blood urea nitrogen, serum creatinine, and histological analysis (H&E staining) were used to
examine renal function and damage. d–f C57BL/6 mice were treated with cisplatin (30mg/kg, intraperitoneal injection), and BUN, serum creatinine, and
histological analysis were conducted at the indicated timepoints. g Representative H&E staining depicting tubular damage (indicated by asterisk) in both
ischemic and cisplatin-treated mice. The graphs (a–f) represent data from a single experiment (n= 5 biologically independent samples), from one out of
three independent experiments, all producing similar results. h Renal tissues from control, ischemic, and cisplatin-treated mice were used for western blot
analysis of indicated proteins. Data presented are representative of five independent experiments, which yielded similar results. i–k Cdkl5 was
immunoprecipitated from the kidneys of control, ischemic, and cisplatin-treated mice, followed by in vitro kinase assays. The representative western blots
show the levels of Cdkl5 immunoprecipitated from tissue samples. The graphs represent data from a single experiment (n= 6 biologically independent
samples), from one out of four independent experiments, all producing similar results. l Ggt1-Cre mice were crossed with ROSAmT/mG mice to generate
transgenic mice that express membrane-localized EGFP in renal tubular epithelial cells. A representative image shows EGFP expression in renal tubular
cells. Arrows with dotted lines indicate tubular cells, while arrows with solid line show the glomerulus. m Schematic representation of the procedure used
to isolate EGFP-positive renal epithelial cells. n Cdkl5 immunoprecipitation and in vitro kinase assay from indicated cells. The graph (n= 4) is
representative of two independent experiments. In all the bar graphs, experimental values are presented as mean ± s.e.m. The height of error bar= 1 s.e.
and p < 0.05 was indicated as statistically significant. One-way ANOVA followed by Dunnett’s (a–f and i, j) or Tukey’s multiple-comparison test (n) was
carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (g and i): 100 µm. Source data are provided as a Source
Data file.
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more stable than the wild-type Sox9, while the phospho-mimetic
S199D mutant had significantly reduced stability (Supplementary
Fig. 8b, c). Based on these studies, we hypothesized that Cdkl5-
dependent phosphorylation at Ser-199 suppresses Sox9 function
during AKI.
To test our hypothesis and observe Sox9 phosphorylation
in vivo, we generated an anti-phospho-Ser-199-specific antibody
(Supplementary Fig. 9), and then examined the levels of total and
phosphorylated Sox9 in renal tissues. In the wild-type mice, total
Sox9 protein levels were low in control kidneys; however, its
expression increased during both ischemia–reperfusion and
cisplatin-associated AKI (Fig. 4d–f). Intriguingly, AKI-induced
increase in the Sox9 protein expression had strikingly different
dynamics in the Cdkl5PT−/y mice. First, as compared with wild-
type mice, AKI-associated Sox9 induction occurred at a much
earlier timepoint in the Cdkl5PT−/y mice, and second, the
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Cdkl5-floxed mice. a Representative western blots showing successful knockout in the renal tissues. Littermate control and Cdkl5 conditional knockout male
mice (indicated by Cdkl5PT−/y) were then challenged with bilateral renal ischemia or cisplatin treatment. Bilateral renal ischemia was induced in wild-type
and Cdkl5PT−/y mice for 30min followed by examination of renal structure and function. b Blood urea nitrogen, c serum creatinine, d renal Kim1 mRNA
expression, and e renal histological analysis (H&E) showed that tubular epithelial-specific Cdkl5 deficiency confers protection from ischemia-associated
AKI. Data presented (b–e) are cumulative of two independent experiments (n= 6). Wild-type and Cdkl5PT−/−mice were treated with cisplatin (25mg/kg)
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results. In all the bar graphs, experimental values are presented as mean ± s.e.m. The height of error bar= 1 s.e. and p < 0.05 was indicated as statistically
significant. One-way ANOVA followed by Tukey’s multiple-comparison test was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01,
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magnitude of Sox9 induction was higher in the Cdkl5PT−/y mice.
Interestingly, phospho-Ser-199–Sox9 levels also increased during
AKI in the wild-type mice; however, Sox9 phosphorylation in the
Cdkl5PT−/y kidneys was pointedly suppressed (Fig. 4e, g). We also
examined total and phosphorylated Cdkl5 protein levels in these
tissues (Supplementary Fig. 10). Importantly, the levels of Sox9
mRNA induction during AKI were not significantly different in
the wild-type and Cdkl5PT−/y mice (Supplementary Fig. 11).
Based on these findings, we postulated that Cdkl5 activation
might contribute to AKI, in part through phosphorylation-
dependent regulation of Sox9 function.
Sox9 plays a protective role during AKI. In the murine kidneys,
Sox9 facilitates recovery of renal function after the onset of
AKI44,45. After the initial injury phase, Sox9-expressing RTECs
contribute to regeneration and recovery; however, the role of
Sox9 in the initial injury phase remains unclear. To study the role
of Sox9 in the early acute phase of AKI, we generated RTEC-
specific Sox9-deficient (Sox9PT−/−) mice (Fig. 5a), which had
normal renal function under baseline conditions (Supplementary
Fig. 5e, f). Importantly, Sox9 deficiency markedly increased renal
damage in both the ischemia (Fig. 5b–e) and cisplatin-associated
(Fig. 5f–i) AKI. Primary RTECs with Sox9 gene ablation were also
sensitive to cisplatin-mediated cell death (Fig. 5j, k). Interestingly,
unlike the normal untreated kidneys (which have very low Sox9
expression), the primary RTECs expressed clearly detectable
levels of Sox9 and were used for further studies. We carried out
“add-back” experiments in the Sox9−/− primary RTECs and
found that S199A mutation provided significantly higher pro-
tection than the WT Sox9, while S199D mutant had minimal
effects, which could be partly due to reduced S199D stability
during cisplatin treatment (Supplementary Fig. 12). These results
suggest that Sox9 plays a protective role during the early phase of
AKI, and Cdkl5-mediated phosphorylation at S199 site likely
reduces its functional activity.
To elucidate the underlying mechanisms, we next carried out
chromatin immunoprecipitation (ChIP)-based analysis of Sox9
target genes in normal and injured kidneys (Supplementary
Fig. 13a). Targets were selected based on ChIP-seq analysis in a
previous study46 and included genes known to be differentially
regulated during AKI47. Our results show that during ischemic
injury, Sox9 binds to the promoter region (±2 kb of transcription
start sites) of several genes (Wwp2, Ap2β, Pi3kca, Myof, sema3e,
and Gadd45a). For Wwp2, myof, Sema3e, and Gadd45a, these
findings were confirmed in three distinct models of AKI
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(Supplementary Fig. 13b–e). For further confirmation, gene
expression analysis was carried out, which showed that as
compared with the littermate controls, renal tissues of Sox9PT−/−
mice have diminished mRNA expression of Wwp2, Myof, and
Sema3e, while Gadd45a expression is elevated (Supplementary
Fig. 14). In the Cdkl5PT−/y mice, which had elevated levels of
Sox9 protein during AKI, the mRNA levels of Sox9-dependent
pro-survival genes (Wwp2, Myof, and Sema3e) were significantly
increased, while Gadd45a gene expression was reduced (Supple-
mentary Fig. 15). Luciferase-based reporter assays confirmed
Sox9 binding within the promoter regions of Wwp2, Myof, and
Sema3e genes (Supplementary Fig. 16). Finally, functional studies
show that Wwp2, Myof, and Sema3e knockdown sensitizes
RTECs to injury, while Gadd45a knockdown provides protection
from cell death (Supplementary Fig. 17). Thus, by increasing the
expression of pro-survival genes like Wwp2, myof, and sema3e,
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Sox9 likely promotes cellular survival during AKI. These genes
are known to regulate phosphoinositide 3-kinase (PI3K)—
phosphatase and tensin homolog (PTEN) signaling (Wwp2)48,
membrane and mitochondrial functions (Myoferlin)49,50, and cell
death (Sema3e)51 in nonrenal epithelial cells. Whether these
genes regulate RTEC dysfunction and cell death in vivo through
similar mechanisms remains unknown. Notably, along with
Wwp2, Myof, and Sema3e, Sox9-dependent renal protective
transcriptional program likely involves multiple target genes that
would require further exploration. However, our results support
the notion that by suppressing Sox9 function, Cdkl5 subdues and
delays a Sox9-dependent protective transcriptional program,
contributing to epithelial-cell death and AKI.
Targeted Cdkl5 inhibition mitigates renal injury in vivo.
Genetic Cdkl5 ablation alleviated renal injury, raising the prospect
that a targeted Cdkl5-kinase inhibitor might prevent or reduce
renal injury. While CDKL5-specific inhibitors have not been
specifically pursued, several known protein kinase inhibitors have
been tested for their ability to inhibit CDKL5 in global kinome-
wide assays52. Based on these studies, we compiled a panel of
small molecules with demonstrated CDKL5 inhibition activity.
We then tested these compounds for their ability to inhibit Cdkl5
function using in vitro kinase assays (Fig. 6a). Among these
inhibitors, AST-487 was found to be the most potent Cdkl5
inhibitor (EC50= 87 nM). AST-487 also inhibited Cdkl5 activity
in BUMPT cells and provided protection from cisplatin-induced
cell death (Supplementary Fig. 18a–d). While AST-487 potently
inhibited Cdkl5 activity, similar to most kinase inhibitors, AST-
487 likely inhibits multiple kinases including RET kinase53. To
examine the role of Cdkl5 inhibition in the renal protective effect
of AST-487, we thus utilized a chemical genomics approach54,55.
To this end, we generated a Cdkl5 construct with a gatekeeper
mutation (F89A), which confers resistance to AST-487-mediated
kinase inhibition (Supplementary Fig. 18e). Importantly, over-
expression of Cdkl5-gate-keeper mutant abrogated AST-487-
mediated protection from cisplatin-induced cell death (Supple-
mentary Fig. 18f–h). Since an AST-487-resistant Cdkl5 mutant is
able to reverse the cytoprotective effects of AST-487, these studies
provide compelling evidence that AST-487-mediated Cdkl5
inhibition is at least partly responsible for its renal protective
effects.
To ascertain the potential efficacy of AST-487 in vivo, we
performed pilot assessment studies. Oral administration of a
single dose of 25 mg/kg AST-487 reduced Cdkl5-kinase activity in
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the kidneys by ~90% (Fig. 6b). Remarkably, AST-487 treatment
(single dose of 25 mg/kg, 6 h after cisplatin injection or ischemic
surgery) significantly reduced cisplatin and ischemia-associated
AKI in the wild-type mice (Fig. 6c–h). We then carried out
further studies in both control and Cdkl5-deficient mouse models.
We found that AST-487 treatment reduced Cdkl5 phosphoryla-
tion and kinase activity (Supplementary Fig. 19a, b). Importantly,
AST-487 treatment did not afford protective effects in the Cdkl5-
deficient mice (Supplementary Fig. 19c–e). Furthermore, AST-
487 treatment in wild-type mice resulted in blunted Sox9
phosphorylation and markedly increased accumulation of Sox9
during AKI (Fig. 6i and Supplementary Fig. 20). Even though
AST-487 treatment conferred protection in the wild-type mice,
we questioned if Cdkl5 inhibition just delays the development of
kidney injury or it has long-term protective effects. Indeed, long-
term survival experiments showed that AST-487 treatment
reduces cisplatin-associated mortality (Supplementary Fig. 21a).
In further support, genetic Cdkl5- deficiency also provides long-
term protection and survival benefits (Supplementary Fig. 21b).
Sox9-dependent and -independent regulation of AKI. To
examine the dependence of Sox9 pathway in Cdkl5-associated
renal injury, we initially examined the effect of Cdkl5 inhibition
in control and Sox9-deficient mice challenged with ischemic
injury. We found that Cdkl5 inhibition provides protection in
both WT and Sox9PT−/− mice; however, the extent of protection
is much lower in the Sox9PT−/− mice (Fig. 7a–c). Mice treated
with cisplatin showed a similar phenotype (Supplementary
Fig. 22a–c). We confirmed these results in primary RTECs, where
Cdkl5 inhibition protected both WT and Sox9−/− cells; however,
the extent of protection was lower in the Sox9−/− cells (Supple-
mentary Fig. 23a–c).
To corroborate these findings, we next used the genetic
knockout approach and performed similar studies in control,
single-, and double-knockout mice (dKOPT) (Fig. 7d). As
compared with the Cdkl5PT−/y mice, the dKOPT mice showed
higher injury when challenged with ischemia, while as compared
with the Sox9PT−/− mice, the dKOPT mice showed lower injury
(Fig. 7d, g). We observed similar results in the cisplatin-toxicity
model (Supplementary Fig. 22d–f). Studies with primary RTECs
with single- or double-gene ablation also confirmed the in vivo
findings (Supplementary Fig. 23d–g). These results suggest that
Cdkl5 regulates renal injury in both Sox9-dependent and
-independent manner. Furthermore, it is likely that regulation
of Sox9 function during AKI occurs in both Cdkl5-dependent and
-independent manner.
Finally, we performed a series of studies in female mice. We
found that similar to male mice, Cdkl5 activity increases during
AKI in females, and genetic or pharmacological inhibition of
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Cdkl5 function provides protection from ischemia and cisplatin-
associated AKI (Supplementary Figs. 24 and 25). Cdkl5-
dependent Sox9 phosphorylation was also confirmed in female
mice (Supplementary Fig. 26). Collectively, these proof-of-
principle experiments in multiple AKI mouse models showed
robust therapeutic effects of Cdkl5 inhibition.
Discussion
Here, we have found that Cdkl5 also known as serine/threonine
kinase 9 (Stk9) is a stress–responsive kinase that controls
epithelial-cell fate during AKI. We propose that Cdkl5 activation
promotes renal dysfunction through phosphorylation-mediated
functional suppression of pro-survival transcription factor Sox9.
Very little is known about the five members of the CDKL family
(CDKL1–5), though they have been linked to certain neuronal
functions56. In humans, mutations in the X-linked CDKL5 gene
are associated with neurodevelopmental disorders characterized
by infantile seizures and developmental delay22,35,57–60. Some of
these phenotypes have been recapitulated in the germline Cdkl5-
knockout mice27. Most studies on CDKL5 function remain pre-
dominantly focused on its role in neuronal development. Inter-
estingly, CDKL5 expression is not restricted to the brain, but is
also detected in peripheral organs, particularly testes and kidney20.
Our studies demonstrate Cdkl5 expression in RTECs and reveal its
functional activation during AKI. It is noteworthy that germline or
renal epithelial-cell-specific Cdkl5 deficiency did not have any
overt effect on normal kidney structure or function. Importantly,
germline or RTEC-specific Cdkl5 deletion conferred significant
protection from AKI. Primary RTECs with Cdkl5 deficiency were
also resistant to cellular injury. These studies suggest that Cdkl5 is
not required for normal renal development or function; however,
under stress conditions, Cdkl5 contributes to renal cell death and
dysfunction.
The CDKL family shares structural features with CDKs as well
as MAPKs and glycogen synthase kinases56. Although their
nomenclature suggests similarity with CDKs, CDKLs have several
features that distinguish them from CDKs, including the lack of
evidence that CDKLs require cyclin binding, the presence of
variant PSTAIRE motifs within the C helix, and large C-terminal
regulatory domains with nuclear localization signals56. Moreover,
there is no clear evidence that CDKLs are involved in cell-cycle
regulation. Interestingly, our studies suggest that Cdkl5 might be
a cell-cycle-independent stress–responsive kinase in RTECs, with
much more functional similarity with MAPKs than CDKs. In
support of this notion, our studies show Cdkl5 activation under
markedly distinct conditions of cellular stress both in vitro and
in vivo. In this regard, Cdkl5 seems to share functional simila-
rities with MAPKs, which are known components of cellular
stress response pathways61.
While the upstream signaling remains unknown, we have
identified the transcription factor Sox9 as a bona fide
Cdkl5 substrate and a key downstream target in renal epithelial
cells. The endogenous substrates of CDKL5 have been previously
investigated to understand its function in neurons25,35–39. Whe-
ther these previously identified substrates are involved in Cdkl5-
dependent renal cell death remains unclear. However, through a
pull-down experiment, we identified Sox9 as a Cdkl5 substrate in
RTECs. Sox9 is a transcription factor that controls cell-fate
decisions during embryonic development and homeostasis of a
broad range of adult tissues62–64. Moreover, in cancer cells, SOX9
inhibits apoptosis and promotes proliferation, invasion, and
metastasis65–67. Interestingly, two recent studies44,45 have shown
that transcriptional upregulation of Sox9 is an early cellular
response to renal injury, and Sox9 is essential for repair and
recovery post AKI. After the initial injury phase, Sox9-expressing
renal epithelial cells play a crucial role in the subsequent repair
processes. Here we show that renal tubule-specific conditional
Sox9-knockout mice are hypersensitive to AKI, indicating that
along with its role in recovery and repair, Sox9 plays a pro-
survival role in the early phase of AKI.
We also found that Cdkl5 phosphorylates Sox9 at Ser-199
residue during kidney injury in vivo. Cdkl5-mediated phos-
phorylation seems to reduce the stability of Sox9 protein. Indeed,
while the injury-induced transcriptional upregulation of Sox9 was
similar in the control and Cdkl5-null mice, Cdkl5 deletion in
RTECs both hastened and markedly increased the accumulation
of Sox9 protein (Fig. 4). Pharmacological inhibition of Cdkl5
kinase also resulted in increased accumulation of Sox9 during
AKI (Fig. 6). Importantly, examination of the protein stability of
various Sox9 mutants (S199A >WT > S199D) indicated that Sox9
phosphorylation at Ser-199 likely causes increased proteasomal
degradation resulting in diminished half-life. However, we cannot
rule out the possibility that Sox9 phosphorylation at Ser-199
might have other biological effects, including changes in dimer-
ization or altered binding to partner proteins. Ser-199 phos-
phorylation might also alter the affinity of Sox9 for target genes, a
possibility that we cannot currently examine due to the inability
to perform ChIP with the phospho-Sox9 antibody. However,
these studies have revealed robust Cdkl5-dependent Sox9 phos-
phorylation in RTECs as part of cellular stress response to distinct
injuries.
AKI is associated with a high risk for mortality, development of
chronic kidney disease, and multi-organ dysfunction2,10. Cur-
rently, no specific treatments or prophylactic approaches are
available to treat or prevent AKI. We provide proof-of-principle
studies showing that targeted Cdkl5 inhibition can provide pro-
tection from renal injury. The small-molecule Cdkl5 inhibitor
AST-487 mitigated renal injury in multiple mouse models of AKI.
While these studies provide promising proof-of-concept data,
clinical translation of these studies would depend on the devel-
opment or identification of Cdkl5 inhibitors with much more
specificity than AST-487. Our study also raises three important
questions that require further exploration. First, in adults, could
systemic Cdkl5 inhibition cause toxicity in the central nervous
system? While Cdkl5 is clearly important for early neuronal
development, it is unclear if it has any essential function in the
adult brain and so, it remains unknown whether short-term
pharmacological Cdkl5 inhibition would have any CNS toxicities.
However, we propose that the likelihood of any neuronal side
effects could be easily reduced by selecting Cdkl5 inhibitors that
do not cross the blood–brain barrier. Second, could systemic
Cdkl5 inhibition cause toxicity in other peripheral organs or
influence renal recovery, regeneration, and fibrosis? Future stu-
dies would be required to examine these possibilities; however, we
have found that Cdkl5 inhibition not just delays renal injury, but
also confers long-term survival benefits, without overt systemic
toxicities (Supplementary Fig. 21). Third, it would be critical to
examine if Cdkl5 inhibition-dependent Sox9 stabilization has any
detrimental long-term effects in the kidneys.
Our study also raises the possibility that the Cdkl5–Sox9 axis
might have important biological functions in other nonrenal cell
types, especially neurons and cancer cells. An essential question
that merits further investigation is whether disruption of
CDKL5–SOX9 axis underlies some of the neuronal phenotypes
observed in humans and mice with loss-of-function CDKL5
mutations. Moreover, SOX9 has emerged as an essential regulator
of cancer cell stemness, differentiation, and apoptosis. We find
that CDKL5 is widely expressed in cancer cell lines (Supple-
mentary Fig. 27), raising the possibility that CDKL5 might reg-
ulate SOX9 function in cancer cells. CDKL5 might be a crucial
nuclear kinase that suppresses SOX9 function under conditions of
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cellular stress. Future studies will likely provide insights into these
important questions and a better understanding of the biological
function of the enigmatic CDKL family of kinases.
Methods
Cell culture and reagents. Boston University mouse proximal tubule cells
(BUMPT, clone 306, originally from Drs. Wilfred Lieberthal and John Schwartz,
Boston University School of Medicine, Boston, MA, and obtained from Dr. Zheng
Dong, Augusta University, Augusta, GA) were grown at 37 °C in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum. The human renal tubular
cell line, HK-2 cells (ATCC, CRL-2190) were grown in keratinocyte media (K-
SFM) according to the provider’s instructions. Protein kinase inhibitors were
obtained from Sigma-Aldrich or Selleckchem. Radiolabeled compounds were
obtained from American Radiochemicals or Moravek Biochemicals.
Primary tubular cell culture and transduction. Anti-GFP antibody and MACS
columns (Miltenyi Biotech) were used to isolate GFP-positive tubular epithelial
cells. For primary cell culture, tubular epithelial cells were isolated from 6- to 8-
week-old male mice24. Briefly, mice were euthanized by carbon dioxide asphyx-
iation, kidneys were excised, and renal cortical tissues were minced thoroughly and
digested with 0.75 mg/ml collagenase IV (Thermo Fisher Scientific). RTECs were
then purified by centrifugation at 2000 g for 10 min in DMEM/F-12 medium with
32% Percoll (Amersham). After washes with serum-free media, the cells were
plated in collagen-coated dishes and cultured in DMEM/F-12 medium supple-
mented with 5 μg/ml transferrin, 5 μg/ml insulin, 0.05 μM hydrocortisone, and
50 μM vitamin C (Sigma-Aldrich). Fresh media was supplemented every alternate
day, and after 5–7 days of growth, the isolated proximal tubular cells were tryp-
sinized and replated at 1 × 105 cells per well in 24-well plates. For Cre-mediated
gene excision, cultured primary tubular cells were transduced with high-titer (1 ×
108 CFU/ml) LV-CMV-Cre-GFP lentivirus (Kerafast), followed by cisplatin treat-
ment 48 h later. Microscopic examinations were carried out to ensure that greater
than 90% cells were GFP (Cre) positive before proceeding with cisplatin treatment.
For Sox9 “add-back” experiments, proximal tubular cells from WT and Sox9PT−/−
cells were transduced with either lentivirus (pLenti-C-Myc-DDK-P2A-Puro, Ori-
gene) encoding WT or Sox9 mutants (S199A and S199D). To induce cell death,
primary RTECs were incubated with 50 μM cisplatin (Sigma-Aldrich) in fresh
culture medium for 24 h, followed by viability and caspase assays.
siRNA kinome screening. BUMPT cells were used for the siRNA kinome
screening using methods similar to our previous study55. Briefly, the Dharmacon
mouse siRNA library targeting protein kinases and related genes (780 genes)
containing four pooled siRNAs for each gene was utilized in the primary screen.
Briefly, the BUMPT cells were plated in 96-well plates and reverse-transfected with
25 nM siRNA using Lipofectamine RNAiMAX reagent (Life Technologies). At 48 h
post transfection, cells were treated with 15 µM cisplatin in fresh media. Subse-
quently, 48 h post treatment, CellTiter-Glo luminescent cell viability assay (Pro-
mega) was carried out to determine cellular viability. The siRNAs that protected
BUMPT cells from cisplatin-induced cell death greater than the positive control
(Pkcδ siRNA) were selected for secondary screening. The primary screen was
carried out in triplicate samples, and data analysis was performed according to
established methods55.
Cell viability and caspase assays. Cellular viability was examined using three
different assays, namely MTT, CellTiter-Glo, and trypan blue staining. MTT assays
were performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reagent (Sigma-Aldrich). BUMPT cells or RTECs were seeded in 96-
well plates, followed by cisplatin treatment for 24–48 h. After treatment, 10 μL of
MTT reagent (5 mg/mL MTT in PBS) was added to each well, and plates were
incubated at 37 °C with 5% CO2 for 4 h, followed by addition of 100 μl of acidified
isopropanol (Sigma-Aldrich) and measurement of absorbance at 590 nm. The half-
maximal inhibitory concentration (IC50) was evaluated by nonlinear regression
analysis using GraphPad Prism. Similar to MTT assays, CellTiter-Glo (Promega)
assays were performed according to established methods followed by luminescence
measurement. Cell viability was also measured by trypan blue exclusion method.
Briefly, cells were harvested, followed by trypan blue staining and manual cell
counting with a hemocytometer and/or by using Countess Automated Cell Counter
(Thermo Fisher); translucent cells were considered as viable and blue-stained cells
were counted as dead. Cell viability was calculated by dividing the number of viable
cells by the total cell number; each sample was done in triplicate.
Caspase activity was measured in cell lysates using an in vitro assay68. Briefly,
RTECs were lysed in a buffer containing 1% Triton X-100, and 10 μg of protein
from cell lysates was added to an enzymatic assay buffer containing 50 μM DEVD-
AFC for 60 min at 37 °C. Fluorescence at excitation 360 nm/emission 535 nm was
measured, and free AFC was used to plot a standard curve, and using the standard
curve, the fluorescence reading from the enzymatic reaction was converted into the
nM AFC liberated per mg protein per hour as a measure of caspase activity.
Mice breeding. All animals were housed and handled in accordance with
approved Institutional Animal Care and Use Committee procedures. All animal
studies were conducted according to protocols approved by the Institutional
Animal Care and Use Committees of The Ohio State University (2017R00000006).
Mice used in the current study were housed in a temperature-controlled envir-
onment with a 12-h light cycle and given a standard diet and water ad libitum.
Germline Cdkl5-deficient mice (stock no. 021967) were obtained from Jackson
Laboratories, and heterozygous mice were bred in-house to obtain wild-type and
knockout littermates. Conditional gene knockout in RTECs was achieved through
breeding of Cdkl5-floxed mice (Jackson Laboratory, stock no. 030523) and Sox9-
floxed mice (Jackson Laboratory, stock no. 013106) with Ggt1-Cre mice (Jackson
Laboratory, stock no. 012841). Double-knockout mice (dKOPT) were generated by
crossing Cre-positive Cdkl5 and Sox9-floxed mice. mT/mG mice that express cell
membrane-targeted, two-color fluorescent Cre-reporter allele were obtained from
Jackson Laboratories (stock no. 007676). In these mice prior to Cre recombination,
cell membrane-localized tdTomato (mT) fluorescence expression is widespread in
cells/tissues, and Cre recombinase expression induces cell membrane-localized
EGFP (mG) fluorescence expression replacing the red fluorescence. The mT/mG
mice were bred with Ggt1-Cre strain. For all mouse colonies, the pups were ear-
tagged and genotyped at 3 weeks of age.
Animal models of AKI. For all experiments, age-matched (8–12 week) male or
female mice were used. Littermates were used in studies with germline, mutant, or
conditional knockout mice. For experiments where only wild-type mice were used,
8- to 12-week-old male C57BL/6J or FvB mice were obtained from Jackson
Laboratories.
For cisplatin nephrotoxicity experiments, cisplatin (15–30 mg/kg) was
administered by i.p. injection24. Optimal cisplatin dose was determined for each
strain by dose–response experiments. After cisplatin injection, blood was collected
on days 0–3 by submandibular vein bleed or on day 3 via cardiac puncture after
carbon dioxide asphyxiation. Renal tissues were collected and processed for
Western blot and histological analysis.
For ischemia–reperfusion experiments, mice were anesthetized by isoflurane
and placed on a surgical platform where the body temperature was monitored
throughout the procedure. The skin was disinfected, kidneys were exposed, and
bilateral renal pedicles were clamped for 28–35 min. Subsequently, the clamps were
released to initiate the reperfusion followed by suturing to close the muscle and
skin around the incision. To compensate for the fluid loss, 0.5 ml of warm sterile
saline was administered via intraperitoneal injection. Blood was collected on days
0–2 by submandibular vein bleed or on day 2 via cardiac puncture after carbon
dioxide asphyxiation. Renal tissues were collected and processed for Western blot
and histological analysis. For Cdkl5 pharmacological inhibition studies, vehicle
(1:10 v/v N-methylpyrrolidone/PEG300) or AST-487 were administered by oral
gavage (25 mg/kg) 6 h post cisplatin injection or ischemic surgery.
To induce rhabdomyolysis, 8–12-week-old male C57BL/6J mice were injected
with 7.5 ml/kg 50% glycerol intramuscularly to the two hind legs or injected with
saline as a control, followed by blood and tissue collection on day 0–2. To induce
FA-mediated kidney injury, male FvB wild-type mice (~25 g, 10 weeks old) were
purchased from Jackson Laboratory and administered with FA (250 mg/kg,
dissolved in 300 mM NaHCO3) through intraperitoneal injection.
Assessment of renal damage. Renal damage was assessed by serum analysis
(blood urea nitrogen and creatinine), histological examination (H&E staining), and
analysis of renal expression of injury biomarkers (Kim1 and Ngal). Mouse blood
samples were collected at indicated timepoints, followed by blood urine nitrogen
and creatinine measurement by QuantiChromTM Urea Assay Kit (DIUR-100) and
Creatinine Colorimetric Assay Kit (Cayman Chemical). For histological analysis,
mouse kidneys were harvested and embedded in paraffin at indicated timepoints
before and after AKI induction. Tissue sections (5 µm) were stained with hema-
toxylin and eosin by standard methods. Histopathologic scoring was conducted in
a blinded fashion by examining ten consecutive 100× fields per section from at least
three mice per group. Tubular damage was scored by calculation of the percentage
of tubules that showed dilation, epithelium flattening, cast formation, loss of brush
border and nuclei, and denudation of the basement membrane. The degree of
tissue damage was scored based on the percentage of damaged tubules as pre-
viously24 described: 0: no damage; 1: <25%; 2: 25–50%; 3: 50–75%; 4: >75%.
Gene expression analysis. Total RNA was extracted from cell lines and murine
kidneys using the RNeasy Mini Kit (Qiagen). NanoDrop was used to measure RNA
quality and quantity. One microgram of total RNA was then reverse-transcribed
using the high-capacity cDNA Reverse Transcription Kit (Thermo Fisher Scien-
tific). qPCR analysis was then performed using the SYBR green master mix with
sequence-specific predesigned primers (Sigma). The sequences of qPCR primers
are shown in Supplementary Table 2. For quantitative analysis, target gene values
were normalized to β-actin gene expression using the ΔΔCT value method.
Protein analysis. Whole-cell lysates from RTECs, cell lines, and renal cortical
tissues were made in modified RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 2.5 mM sodium pyrophosphate,
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1 mM beta-glycerophosphate, protease, and phosphatase inhibitors) supplemented
with 1% SDS. Cellular lysates for CDKL5 immunoprecipitation and kinase assay
were made in modified RIPA buffer supplemented with 0.1% SDS. For co-
immunoprecipitation experiments, cell lysates were made in modified RIPA buffer
supplemented with 0.2% β-maltoside. Immunoprecipitations were carried out as
described previously55 using anti-FLAG (EZview Red ANTI-FLAG M2 Affinity
Gel, Sigma-Aldrich), anti-CDKL5 (Millipore, MABS1132), and anti-SOX9 anti-
bodies (Abcam, ab3697). Invitrogen Bis-tris gradient mini or midi-gels were used
for western blot analysis, followed by detection by ECL reagent (Cell Signaling).
Primary antibodies used for western blot analysis were from Cell Signaling: FLAG
(14793), Histone H3 (4499), GAPDH (5174), and Santa Cruz Biotech: β-actin
(47778), NGAL (50351), Myoferlin (376879), Sema3e (74554), Gadd45a (6850),
Abcam: SOX9 (EPR14335-78), and CDKL5 (ab22453). All primary antibodies were
used at 1:1,000 dilution. Secondary antibodies were from Jackson Immunoresearch
and used at 1:2,000 dilutions. Uncropped images of western blots are shown in
Source Data File. Protein lysates used to determine CDKL5 expression in cancer
cell lines were obtained from the DCTD Tumor Repository, National Cancer
Institute at Frederick, and the list of cell lines is provided in Supplementary Table 3.
Protein kinase assay. Protein kinase assays of purified proteins and IP kinases
were carried out by in vitro assays55,68. For assays with purified proteins, CDKL5-
recombinant human protein was obtained from Life Technologies (A30493). To
purify Sox9 wild-type and mutant proteins, FLAG-tagged Sox9 constructs were
subcloned into pT7CFE1-CHis plasmid (Thermo Fisher). These constructs were
then used for in vitro translation using a HeLa cell lysate-based Kit (1-Step Human
Coupled IVT Kit—DNA, 88881, Life Technologies). The in vitro-translated pro-
teins were then purified using His Pur cobalt spin columns (Thermo Scientific). For
in vitro kinase assays, recombinant CDKL5 and purified Sox9 proteins were
incubated in a kinase buffer (Cell Signaling, 9802) supplemented with [gamma-
P32] adenosine 5′-triphosphate (ATP) at 30 °C for 30 min. After the incubation
period, the reaction was terminated, followed by autoradiographic examination of
phosphorylated proteins and subsequent western blot analysis to determine the
level of input proteins. For assays used to examine multiple kinase inhibitors,
purified kinases (CDK2, CDK4, CDK6, and CDKL5) were incubated with 1 µM
concentration of kinase inhibitors for 30 min followed by kinase assays using ADP-
Glo Kinase Assay kit (Promega).
Renal tissues and cells were lysed with a buffer containing 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% (vol/vol) Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerol phosphate, 1 mM Na3VO4, 10 μg/ml leupeptin, 10 μg/ml
aprotinin, 1 mM phenylmethylsulfonyl fluoride, 50 mM NaF, 0.2% (wt/vol)
dodecyl β-D-maltoside, and 20 mM Tris (pH 7.5). The soluble extracts were then
subjected to Cdkl5 immunoprecipitation. Briefly, 500 µg of protein lysate was
incubated with 2 μg of IgG or anti-Cdkl5 antibody at 4 oC overnight, followed by
addition of 30 μl of agarose protein A/G beads. Bead-bound immunoprecipitates
were washed and collected by centrifugation. Immunoprecipitates were added to a
protein kinase reaction buffer containing 20 µM ATP and myelin basic protein
(Millipore) as substrate and incubated at 30 °C for 30 min. The ADP-Glo™ Kinase
Assay (Promega) kit was then used to measure kinase activity. This is a luminescent
ADP detection assay that provides a method to measure kinase activity by
quantifying the amount of ADP produced during a kinase reaction. After the
reaction was terminated, western blot analysis was carried out to determine the
level of inmmunoprecipiated proteins. Relative kinase activity was calculated by
normalizing the kinase activity (luminescence) to the amount of IP protein
(densitometry of Cdkl5 signal). The specificity of Cdkl5-kinase assay was verified
by conducting assays using wild-type and Cdkl5−/y tissues, which demonstrated
undetectable activity in the Cdkl5-deficient tissues (Supplementary Fig. 19a, b).
Mass spectrometry analysis. Mass spectrometric analysis was performed at the
Taplin Biological Mass Spectrometry Facility (Harvard University). Excised gel
bands were cut into approximately 1-mm3 pieces. Gel pieces were then subjected to
a modified in-gel trypsin digestion procedure69. Gel pieces were washed and
dehydrated with acetonitrile for 10 min, followed by removal of acetonitrile. Pieces
were then completely dried in a speed-vac. Rehydration of the gel pieces was with
50 mM ammonium bicarbonate solution containing 12.5 ng/µl modified
sequencing-grade trypsin (Promega, Madison, WI) at 4 °C. After 45 min, the excess
trypsin solution was removed and replaced with 50 mM ammonium bicarbonate
solution to just cover the gel pieces. Samples were then placed in a 37 °C room
overnight. Peptides were later extracted by removing the ammonium bicarbonate
solution, followed by one wash with a solution containing 50% acetonitrile and 1%
formic acid. The extracts were then dried in a speed-vac (~1 h) and reconstituted in
5–10 µl of HPLC solvent A (2.5% acetonitrile and 0.1% formic acid). A nanoscale
reverse-phase HPLC capillary column was created by packing 2.6-µm
C18 spherical silica beads into a fused silica capillary (100-µm inner diameter ×
~30-cm length) with a flame-drawn tip. After equilibrating the column, each
sample was loaded via a Famos auto sampler (LC Packings, San Francisco, CA)
onto the column. A gradient was formed and peptides were eluted with increasing
concentrations of solvent B (97.5% acetonitrile and 0.1% formic acid). As peptides
eluted, they were subjected to electrospray ionization and then entered into an LTQ
Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Wal-
tham, MA). Peptides were detected, isolated, and fragmented to produce a tandem
mass spectrum of specific fragment ions for each peptide. The peptides were
fragmented using CID (collision-induced disassociation). A high-resolution scan
was done at 60,000 resolutions, followed by 20 low-resolution MS/MS scans in the
ion trap. Peptide sequences (and protein identity) were determined by matching
protein databases (Uniprot) with the acquired fragmentation pattern by the soft-
ware program, Sequest Version 3.2 (ThermoFisher, San Jose, CA). The database
was indexed based on a trypsin digestion, with two missed cleavages. Fixed
modification of 57.0214 Da on cysteine (iodoacetamide) and a variable modifica-
tion of 15.9949 Da on methionine were considered. The MS1 mass tolerance was
50 ppm and the MS2 tolerance was 1.0 Da. The peptide mass range used was
600–6000 Da. All accepted peptides have a cross-correlation (Xcorr) score of at
least 0.5. All databases include a reversed version of all the sequences, and the data
were filtered to between a 1 and 2% peptide false-discovery rate. For analysis, we
applied a cutoff of five unique peptides per protein. The peptides used for iden-
tification of Sox9 are shown in Supplementary Table 4.
Generation of phospho-Ser-199–SOX9 and phospho-Thr-169-Cdkl5 anti-
bodies. Phospho-specific antibodies were generated and characterized by estab-
lished methods70. Briefly, the rabbit anti-phospho-antibodies were generated by
using the 118-day protocol (Covance). Peptide surrounding the Ser-199 of Sox9
and Thr-169 region of Cdkl5 was used for immunization. Immunoblot and ELISA-
based methods were used to test the bleeds for antibody production, followed by
purification of phospho-antibody by affinity purification. The specificity of the
purified antibody was confirmed with in vitro kinase assays and tissues from
knockout mice. Dephosphorylation assays were carried out by incubation of cell
lysates with recombinant lambda phosphatase (New England Biolabs, P0753) at 30
°C for 2 h, followed by western blot analysis with phospho- and total Sox9 and
Cdkl5 antibodies.
Chromatin immunoprecipitation–qPCR. ChIP assays were performed using the
Pierce Magnetic ChIP Kit according to the manufacturer’s instructions70. Briefly,
cross-linking with 1% formaldehyde was carried out in RTECs or renal tissues,
followed by quenching with glycine, cell harvesting, and DNA fragmentation by
sonication. Lysates were precleared for 1 h with Protein A+G magnetic beads
(EMD Millipore). Precleared lysates were then incubated with 5 μg of anti-SOX9
antibodies (Abcam, ab3697) overnight at 4 °C, followed by addition of Protein A+
G magnetic beads and incubation for 4 h at 4 °C. Subsequently, the beads were
repeatedly washed, followed by elution of the protein–DNA complexes, reversal of
cross-links, and DNA purification. Standard qPCR analysis was then carried out
using primers spanning the promoters of target genes. The sequences of primers
are shown in Supplementary Table 2.
Plasmids and site-directed mutagenesis. The Cdkl5 and Sox9 plasmids with
pCMV6-entry backbone were obtained from Origene. The QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent) was utilized to generate mutants, according to
suggested methods. The QuikChange primer design program was employed to
design mutagenesis primers55. Primers were synthesized by Integrated DNA
Technologies. All constructs were sequenced to confirm successful mutagenesis.
The mutagenesis primer sequences are shown in Supplementary Table 2.
Promoter luciferase assay. HEK293 cells were stably transfected with either
empty vector (pCMV6) or Sox9 expression vector (Origene). These cells were then
utilized for promoter luciferase reporter assays70. Briefly, 5 × 103 cells were plated
overnight on white poly-L-lysine-coated 96-well plates, followed by transient
transfection with either promoter constructs (Switchgear Genomics, encoding 2-kb
sequence upstream of transcription start sites of the following genes: Gadd45a,
Wwp2, Sema3e, and Myof) or empty promoter construct at 30 ng in combination
with the Cypridina TK control construct (Switchgear Genomics) at 1 ng, according
to the manufacturer’s protocol (Switchgear Genomics, Lightswitch Dual Assay kit,
DA010). The promoter construct encodes a Renilla luminescent reporter gene,
called RenSP, while the transfection and normalization vector encodes a Cypridina
luciferase. The Renilla luciferase activity was normalized with the Cypridina luci-
ferase activity.
Statistical considerations. Data are presented as mean with s.e.m., unless stated
otherwise. Statistical calculations (Student’s t test or analysis of variance) were
carried our using GraphPad Prism. p < 0.05 was considered statistically significant.
To calculate statistical significance between two groups, two-tailed unpaired Stu-
dent’s t test was performed. One-way ANOVA followed by Tukey’s or Dunnett’s
multiple-comparison test was used for comparisons among three or more groups.
For all the experimental data presented in the paper, no sample outliers were
excluded.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The source data underlying Figs. 1b, 1d, 1e–h, 2a–f, 2h–k, 2n, 3a–k, 4a, b, 4d–f, 5a–k,
6a–I, and 7a–g and Supplementary Figs. 1a–k, 2a, b, 4a–i, 5a–f, 6a–I, 7, 8a–c, 9a, b,
10a–d, aa, 12a–e, 13a–e, 14a–h, 15a–h, 16, 17a–p, 18a–h, 19a–e, 20, 21a, b, 22a–f, 23a–g,
24a–g, 25a–g, 26a–c, and 27 are provided as a Source Data file. A reporting summary for
this article is available as a Supplementary Information file. All data supporting the
findings of this study are available from the corresponding author on reasonable request.
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